Scarica l'app Stockscreener
2.94
8.46%
-0.25
Dopo l'orario di chiusura:
2.95
0.01
+0.34%
Precedente Chiudi:
$3.19
Aprire:
$3.21
Volume 24 ore:
106.00K
Relative Volume:
1.11
Capitalizzazione di mercato:
$128.36M
Reddito:
-
Utile/perdita netta:
$-78.92M
Rapporto P/E:
-1.4412
EPS:
-2.04
Flusso di cassa netto:
$-72.87M
1 W Prestazione:
-21.08%
1M Prestazione:
-26.26%
6M Prestazione:
-17.05%
1 anno Prestazione:
-27.00%
Intervallo 1D:
$2.89
$3.21
Intervallo di 1 settimana:
$2.89
$3.75
Portata 52W:
$2.47
$6.06
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Nome
Vigil Neuroscience Inc
Settore
Industria
Telefono
857-254-4445
Indirizzo
100 FORGE ROAD, WATERTOWN
Confronta VIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| VIGL | 2.94 | 128.36M | 0 | -78.92M | -72.87M | -2.04 |
| VRTX | 467.12 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.38 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.35 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.83 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-31 | Iniziato | Mizuho | Buy |
| 2022-09-16 | Iniziato | Wedbush | Outperform |
| 2022-08-29 | Iniziato | H.C. Wainwright | Buy |
| 2022-02-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Iniziato | Jefferies | Buy |
| 2022-02-01 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Iniziato | Stifel | Buy |
Mostra tutto
Vigil Neuroscience Inc Borsa (VIGL) Ultime notizie
Citadel Advisors LLC Adjusts Position in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Deep Track Capital, LP Increases Stake in Vigil Neuroscience Inc - GuruFocus.com
Vigil Neuroscience to Present at Upcoming Investor Conferences - GlobeNewswire
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business UpdateOn November 7, 2024, Vigil Neuroscience, Inc. (NASDAQ: VIGL) released its financial results for the third quarter ended September 30, 2024. The company, dedic - Defense World
Vigil Neuroscience’s (VIGL) “Buy” Rating Reiterated at HC Wainwright - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $24.00 - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Given New $24.00 Price Target at Wedbush - MarketBeat
HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience Advances Key Clinical Programs - TipRanks
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) has caught the attention of institutional investors who hold a sizeable 41% stake - Yahoo Finance
Vigil Neuroscience Inc (VIGL) Quarterly 10-Q Report - Quartzy
Vigil Neuroscience to Present at Guggenheim Healthcare Innovation Conference - GlobeNewswire
abrdn plc Makes New $799,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
We Think Vigil Neuroscience (NASDAQ:VIGL) Needs To Drive Business Growth Carefully - Simply Wall St
Vigil Neuroscience retains stock target on TREM2 potential - Investing.com
Vigil Neuroscience retains stock target on TREM2 potential By Investing.com - Investing.com Australia
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Victoria Advocate
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors - BioSpace
Quanterix Appoints Ivana Magovčević-Liebisch to Board of Directors - citybiz
Point72 Asset Management L.P. Buys New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Point72 Asset Management L.P. Acquires New Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Shares Purchased by Ensign Peak Advisors Inc - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 20.3% in September - MarketBeat
Is Vigil Neuroscience (NASDAQ:VIGL) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Certified Advisory Corp Grows Stake in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Purchased by Harmony Asset Management LLC - Defense World
Evergreen Capital Management LLC Sells 380 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Circle Wealth Management LLC Acquires 383 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Garden State Investment Advisory Services LLC Acquires 743 Shares of Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
VICOR 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Vicor CorporationVICR - Business Wire
INVESTOR DEADLINE MONDAY: Robbins Geller Rudman & Dowd LLP Announces that Vicor Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – VICR - ForexTV.com
Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com
WCG Wealth Advisors LLC Has $3 Million Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
Bradley Foster & Sargent Inc. CT Cuts Position in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) - Defense World
1,275 Shares in Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Bought by One Capital Management LLC - Defense World
Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) Shares Sold by ProVise Management Group LLC - Defense World
Vigil Neuroscience shares maintain Outperform rating on positive FDA update By Investing.com - Investing.com Australia
FDA lifts partial clinical hold on Vigil Neuroscience’s Phase I VG-3927 trial - Clinical Trials Arena
FDA lifts hold on Vigil Neuroscience's Alzheimer trial By Investing.com - Investing.com Canada
Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927 - ForexTV.com
Vigil stock gains as FDA removes partial hold (NASDAQ:VIGL) - Seeking Alpha
FDA lifts hold on Vigil Neuroscience's Alzheimer trial - Investing.com India
Vigil Neuroscience Advances Alzheimer’s Trial, Eyes 2025 Data - TipRanks
Vigil Neuroscience Says FDA Lifts Partial Hold Alzheimer's-Treatment Trial - MarketWatch
Vigil Neuroscience rises as FDA lifts partial hold on Alzheimer’s disease trial - XM
The Neuroscience Market Research Explores 2024: Advancing Brain Research and Therapeutics - WhaTech
Vigil Neuroscience to Present at Cantor Global Healthcare Conference - GlobeNewswire
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Update - MarketBeat
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 23.7% in August - Defense World
Vigil Neuroscience Inc Azioni (VIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vigil Neuroscience Inc Azioni (VIGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Nov 20 '23 |
Buy |
3.75 |
4,000 |
15,000 |
207,687 |
4.27%
0.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):